SEARCH:   Advanced

Blood, 1 November 2008, Vol. 112, No. 9, pp. 3591-3593. Prepublished online as a Blood First Edition Paper on July 8, 2008; DOI 10.1182/blood-2008-02-141598. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-02-141598v1 112/9/3591    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rosinol, L. Articles by Blade, J. Search for Related Content PubMed PubMed Citation Articles by Rosinol, L. Articles by Blade, J. Related Collections Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 26, 2008 Accepted June 16, 2008 A prospective pethema study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma Laura Rosinol, Jose Antonio Perez-Simon, Anna Sureda, Javier de la Rubia, Felipe de Arriba, Juan Jose Lahuerta, Jose David Gonzalez, Joaquin Diaz-Mediavilla, Belen Hernandez, Javier Garcia-Frade, Dolores Carrera, Angel Leon, Miguel Hernandez, Pascual Fernandez Abellan, Juan Miguel Bergua, Jesus San Miguel, and Joan Blade* Hematology, Hospital Clinic, Barcelona, Spain Hematology, Hospital Universitario Salamanca, Salamanca, Spain Hematology, Hospital Sant Pau, Barcelona, Spain Hematology, Hospital La Fe, Valencia, Spain Hematology, Hospital Morales Messeguer, Murcia, Spain Hematology, Hospital 12 de octubre, Madrid, Spain Hematology, Hospital Materno-Insular, Las Palmas de Gran Canaria, Spain Hematology, Hospital Clinico San Carlos, Madrid, Spain Hematology, Hospital General Ciudad Real, Ciudad Real Hematology, Hospital Rio Hortega, Valladolid Hematology, Hospital de Asturias, Oviedo Hematology, Hospital de Jerez, Jerez de la Frontera Hematology, Hospital Universitario de Canarias, Sta. Cruz de Tenerife Hematology, Hospital Alicante, Alicante Hematology, Hospital San Pedro de Alcantara, San Pedro de Alcantara * Corresponding author; email: jblade{at}clinic.ub.es. One-hundred and ten patients with multiple myeloma (MM) failing to achieve at least near-complete remission (nCR) after a first autologous stem cell transplant (ASCT) were scheduled to receive a 2nd ASCT (85 patients) or a reduced-intensity-conditioning allograft (Allo-RIC) (25 patients), depending on the HLA-identical sibling donor availability. There was a higher increase in CR rate (40% vs. 11%, p=0.001) and a trend towards a longer progression-free survival (PFS) (median 31 months vs. not reached, p=0.08) in favour of Allo-RIC. In contrast, it was associated with a trend towards a higher transplant-related mortality (16% vs. 5%, p=0.07), a 66% chronic graft-versus-host disease and no statistical difference in event-free survival and overall survival. Although the PFS plateau observed with Allo-RIC is very encouraging, this procedure is associated with a high morbidity and mortality and, therefore, it should be still considered investigational and restricted to well designed prospective clinical trials. This trial is registered at ClinicalTrials.gov ID number NCT00560053. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Is more better in myeloma? Guido Tricot Blood 2008 112: 3532. [Full Text] [PDF] Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma Philippe Moreau, Frédéric Garban, Michel Attal, Mauricette Michallet, Gérald Marit, Cyrille Hulin, Lotfi Benboubker, Chantal Doyen, Mohamad Mohty, Ibrahim Yakoub-Agha, Serge Leyvraz, Philippe Casassus, Hervé Avet-Loiseau, Laurent Garderet, Claire Mathiot, and Jean-Luc Harousseau, on behalf of the IFM group Blood 2008 112: 3914-3915. [Full Text] [PDF] This article has been cited by other articles: A. K. Stewart Reduced-intensity allogeneic transplantation for myeloma: reality bites Blood, April 2, 2009; 113(14): 3135 - 3136. [Full Text] [PDF] M. Rotta, B. E. Storer, F. Sahebi, J. A. Shizuru, B. Bruno, T. Lange, E. D. Agura, P. A. McSweeney, M. A. Pulsipher, P. Hari, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting Blood, April 2, 2009; 113(14): 3383 - 3391. [Abstract] [Full Text] [PDF] B. Bruno, M. Rotta, F. Patriarca, D. Mattei, B. Allione, F. Carnevale-Schianca, R. Sorasio, A. Rambaldi, M. Casini, M. Parma, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo Blood, April 2, 2009; 113(14): 3375 - 3382. [Abstract] [Full Text] [PDF] J. Blade and L. Rosinol Changing paradigms in the treatment of multiple myeloma Haematologica, February 1, 2009; 94(2): 163 - 166. [Full Text] [PDF] D. Reece, J.-L. Harousseau, and M. A. Gertz Nontransplant Therapy of Myeloma, High-dose Therapy for Myeloma, and a Personalized Care Plan for Treatment of Myeloma ASCO Educational Book, January 1, 2009; 2009(1): 502 - 509. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020